| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/15/2001 | CA2383790A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | CA2383788A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | CA2383774A1 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | CA2383086A1 Non-peptidic cyclophilin binding compounds and their use |
| 03/15/2001 | CA2382161A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | CA2381581A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 03/15/2001 | CA2380763A1 Aminoalkoxy carbazoles for the treatment of cns diseases |
| 03/15/2001 | CA2349434A1 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 03/14/2001 | EP1083178A1 Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof |
| 03/14/2001 | EP1083172A1 N-substituted derivatives of 5-oxyiminobarbituric acid |
| 03/14/2001 | EP1083168A1 Prostaglandin derivative |
| 03/14/2001 | EP1082962A1 UTILIZATION OF 2-HYDROXY-4-TRIFLUOROMETHYLBENZO C ACID DERIVATIVES AS INHIBITORS OF THE ACTIVATION OF THE NUCLEAR TRANSCRIPTION FACTORS NF-$g(k)B |
| 03/14/2001 | EP1082961A1 Sleep inducing agent |
| 03/14/2001 | EP1082960A2 Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm |
| 03/14/2001 | EP1082959A1 NK1 Antagonists for the treatment of depression |
| 03/14/2001 | EP1082958A2 5-HT1F agonists in chronic pain |
| 03/14/2001 | EP1082433A1 Interleukins-21 and 22 |
| 03/14/2001 | EP1082426A2 Human socs proteins |
| 03/14/2001 | EP1082334A1 Alg-2lp, alg-2 like molecules and uses therefor |
| 03/14/2001 | EP1082320A1 Novel substituted imidazole compounds |
| 03/14/2001 | EP1082313A1 Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 03/14/2001 | EP1082310A1 Methods of identifying and using hla binding compounds as hla-agonists and antagonists |
| 03/14/2001 | EP1082308A1 Heterocyclically substituted amides used as calpain inhibitors |
| 03/14/2001 | EP1082306A1 Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| 03/14/2001 | EP1082304A1 NEW CRYSTALLINE POLYMORPHIC FORM OF 1-METHYL-5-p-TOLUOYLPYRROLE-2-ACETAMIDOACETIC ACID GUAIACYL ESTER (MED 15) |
| 03/14/2001 | EP1082302A1 A vla-4 inhibitor: omepupa-v |
| 03/14/2001 | EP1082301A1 Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres |
| 03/14/2001 | EP1082292A2 Control of pain with endogenous cannabinoids |
| 03/14/2001 | EP1082289A1 Methods for identifying novel multimeric agents that modulate receptors |
| 03/14/2001 | EP1082142A2 Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |
| 03/14/2001 | EP1082127A1 SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME |
| 03/14/2001 | EP1082120A1 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| 03/14/2001 | EP1082119A1 Microemulsion preconcentrates containing a piperidine substance p antagonist |
| 03/14/2001 | EP1082116A1 Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders |
| 03/14/2001 | EP1082115A1 Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| 03/14/2001 | EP1082113A2 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| 03/14/2001 | EP1082110A1 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 03/14/2001 | EP1082103A1 Spill resistant pharmaceutical compositions |
| 03/14/2001 | EP0804601B1 Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle |
| 03/14/2001 | CN1287555A N-oxides of heterocyclic compounds with TNF and PDE IV inhibiting activity |
| 03/14/2001 | CN1287554A Novel optically active aminopentane derivative |
| 03/14/2001 | CN1287487A Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical composition containing the same |
| 03/14/2001 | CN1287005A Compound Lingxian headache-treating capsule and its preparation |
| 03/14/2001 | CN1287001A Wine-mated oral liquid |
| 03/14/2001 | CN1063181C [(R)-(2)-1-azabicyclo [2,2,1]heptan-3-one, o-[3-(3-methoxyphenyl)2-propynyl] oxime maleate as a pharmaceuticals |
| 03/14/2001 | CN1063180C 5H, 10H-imidazo [1,2-a] indeno [1,2-e] pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives |
| 03/14/2001 | CN1063179C Process for producing imidazodiazepine derivatives |
| 03/14/2001 | CN1063178C Aza-anthracyclinone derivatives |
| 03/14/2001 | CN1063177C Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinayl and pyrimidinylpiperazines |
| 03/14/2001 | CN1063176C Chromone derivative |
| 03/14/2001 | CN1063175C Pyrrolidinyl methyl indole salt |
| 03/14/2001 | CN1063060C Compound Chinese medicine preparation for curing traumatic paraplegia and its producing process |
| 03/13/2001 | US6201025 For treatment of central nervous system disorders |
| 03/13/2001 | US6201021 Pentanoic acid derivatives |
| 03/13/2001 | US6201020 Effective poly(adenosine 5'-diphospho-ribose) polymerase (parp) inhibitor for treatment of tissue damage by necrosis or apoptosis; side effect reduction |
| 03/13/2001 | US6201007 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 03/13/2001 | US6201004 Dioxino derivatives and their use as therapeutic agents |
| 03/13/2001 | US6200999 3-Alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds |
| 03/13/2001 | US6200993 Heterosubstituted pyridine derivatives as PDE4 inhibitors |
| 03/13/2001 | US6200991 Imidazole derivatives, preparation and therapeutic application thereof |
| 03/13/2001 | US6200984 Naphtho-imidazo pyridine derivatives useful in treating central nervous system disorders |
| 03/13/2001 | US6200982 Substituted 1H-pyridinyl-2-ones as GABAA-α 2/3 ligands |
| 03/13/2001 | US6200979 Administering substituted pyrazoles and pyzazolopyrimidines for treating phobias obsessive-compulsive disorder, post-traumatic stress disorder, single episode depression, recurrent depression, dysthymia, bipolar disorders |
| 03/13/2001 | US6200978 For preventing or treating inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function, gastrointestinal disorders such as functional bowel disease, as analgesics |
| 03/13/2001 | US6200975 For cognition enhancement therapy |
| 03/13/2001 | US6200972 Heterocyclic esters and amides |
| 03/13/2001 | US6200970 For treating a disease associated with overstimulation of an ampa receptor, or hyperactivity of an excitatory amino acid |
| 03/13/2001 | US6200968 Particle-forming compositions containing fused pyrrolocarbazoles |
| 03/13/2001 | US6200957 Useful for treatment of variety of sex-hormone related and other conditions in both men and women |
| 03/13/2001 | US6200775 Nucleotide sequence coding a polypeptide associated with the diagnosis and treatment of infections |
| 03/13/2001 | US6200768 Detecting compounds efficient in the dissolution of an alzheimer's protein; incubate preferential protein with kinase, monitor helix formation, incubate with modulator and detect blocking action by modulator |
| 03/13/2001 | US6200758 Detecting a psychological disorders; obtain biopsies, detect nucleotide sequence variation, presence of variation indicates psychological disorders |
| 03/13/2001 | US6200599 Ortho ester lipids |
| 03/13/2001 | CA2146238C Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace |
| 03/08/2001 | WO2001016603A2 Analysis and treatment of body weight and eating disorders |
| 03/08/2001 | WO2001016359A2 Screen for axon viability |
| 03/08/2001 | WO2001016319A2 Compositions and methods for the treatment of immune related diseases |
| 03/08/2001 | WO2001016315A1 sIGH AFFINITY CHOLINE TRANSPORTER |
| 03/08/2001 | WO2001016312A2 Nucleic acid based modulators of gene expression |
| 03/08/2001 | WO2001016304A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 03/08/2001 | WO2001016297A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 03/08/2001 | WO2001016293A2 Dna encoding the human serine protease t |
| 03/08/2001 | WO2001016289A2 Zymogen activation system |
| 03/08/2001 | WO2001016288A2 Dna encoding the human serine protease c-e |
| 03/08/2001 | WO2001016156A1 Attractin-like polynucleotides, polypeptides, and antibodies |
| 03/08/2001 | WO2001016138A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 03/08/2001 | WO2001016137A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 03/08/2001 | WO2001016136A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/08/2001 | WO2001016135A2 Reverse-turn mimetics and methods relating thereto |
| 03/08/2001 | WO2001016134A1 Selective antagonists of a2b adenosine receptors |
| 03/08/2001 | WO2001016121A1 Heterocyclic compounds and methods of use thereof |
| 03/08/2001 | WO2001016120A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 03/08/2001 | WO2001016114A2 Heterocyclic compounds and methods for modulating cxcr3 function |
| 03/08/2001 | WO2001016107A1 Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 03/08/2001 | WO2001016105A1 4-substituted piperidine derivatives |
| 03/08/2001 | WO2001016103A1 Fused pyrrolecarboxamides: gaba brain receptor ligands |
| 03/08/2001 | WO2001016097A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 03/08/2001 | WO2001016093A1 SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF |
| 03/08/2001 | WO2001015736A2 Interferon-beta conjugates |
| 03/08/2001 | WO2001015717A1 Brain cell or nerve cell protecting agents comprising ginseng |